Neurostimulation Devices Market size was valued at USD 11.32 billion in 2024 and is poised to exceed USD 50.56 billion by the end of 2037, registering over 12.1% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of neurostimulation devices is evaluated at USD 12.42 billion.
The market is estimated to grow on the back of increasing neurological surgeries and disorders. According to estimates, about 22 million people suffer from neurological disorders every year, of which 13 million require surgery. Moreover, an increasing number of minimally invasive surgeries across the globe is also anticipated to fuel the growth of the market in the coming years. Additionally, increasing the adoption of neurostimulation devices for the treatment of neurological disorders and increasing patient awareness are also expected to boost the growth of the global market during the forecast period.
The global neurostimulation devices market is also estimated to witness growth on account of the increasing level of the geriatric population globally. According to the World Health Organization (WHO) data, the population aged 60 years and above stood at around 1 billion in 2020, which is projected to reach 1.4 billion by the end of 2030. According to the World Health Organization (WHO) data, the population of people aged 60 years and above in China was around 254 million in 2019, with about 176 million people aged 65 and above. By 2040, it is estimated that there will be about 402 million people over the age of 60 in China. Moreover, the increasing technological advancement and innovation in these neurostimulation devices are anticipated to drive market growth during the forecast period.
Growth Drivers
Challenges
Base Year |
2024 |
Forecast Year |
2025-2037 |
CAGR |
12.1% |
Base Year Market Size (2024) |
USD 11.32 billion |
Forecast Year Market Size (2037) |
USD 50.56 billion |
Regional Scope |
|
End-user (Hospitals, Surgical Centers, Specialty Clinics)
The global neurostimulation devices market is segmented and analyzed for demand and supply by end-user into hospitals, ambulatory surgical centers, and specialty clinics. Out of these segments, the hospitals segment is anticipated to garner the largest market share over the forecast period, owing to the rising healthcare infrastructure globally, and the increasing incidence of chronic pain. As per the data, Indian healthcare infrastructure is projected to grow to USD 345 billion by the end of 2022. In addition, the growing number of hospitals globally is also expected to boost the growth of this segment in the coming years. For instance, there were approximately 6000 hospitals in the United States in 2020.
Product (Spinal Cord Stimulators, Deep Brain Stimulators, Cochlear Implants, Vagus Nerve Stimulators, Sacral Nerve Stimulators, Percutaneous Tibial Nerve Stimulators, Transcranial Magnetic Stimulators)
The global neurostimulation devices market is also segmented and analyzed for demand and supply by product type into spinal cord stimulators, deep brain stimulators, cochlear implants, vagus nerve stimulators, sacral nerve stimulators, and transcranial magnetic stimulators. Out of these segments, by 2037 the spinal cord stimulation segment is anticipated to lead the market in terms of revenue. Some of the factors influencing the growth of this market include the rising prevalence of spinal cord injuries, chronic pain, the rising acceptance of SCS devices, and the attractive reimbursement environment for SCS treatments. As per data, more than 16,900 new cases of spinal cord injuries occur in the United States every year.
Our in-depth analysis of the global market includes the following segments:
By Product Type |
|
By Application |
|
By End-user |
|
The North America region neurostimulation devices market projected to hold the largest market share by the end of 2037. This can be accredited to the increasing prevalence of neurological disorders and the increasing level of the geriatric population in the region. According to statistics, in 2018, approximately 20 million US citizens experience some form of neuropathy, of which approximately 15% are individuals with brain impairment in US households. Further, the market is estimated to gain high growth during the forecast period, owing to the rising use of implantable neurostimulation devices to minimize pain and increasing initiatives to innovate medical devices in the region.
Nevro Corp., a global medical device company, today announced that its Senza system has been successfully approved by the FDA for the treatment of chronic pain associated with painful diabetic neuropathy (PDN). With the approval, the company will immediately begin its commercial production in the United States.
NeuroSigma, Inc., a bioelectronic medical device company, today announced that the company received an equity investment of USD 5 million from KT Corporation, an international digital telecommunication company. With the investment, the company will support the commercialization and development of Monarch eTNS Systems and accelerate the business growth trajectory of NeuroSigma.
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?